The 6-month RCT investigating submacular hemorrhage secondary to nAMD found that both treatment modalities showed clinical improvement of VA, but surgery did not provide a superior visual gain.
/PRNewswire/ CorEvitas, the leading sponsor of registries in autoimmune and inflammatory diseases, and The Guthy-Jackson Charitable Foundation (GJCF) are.